 |
|
The Effects of Amantadine and Pemoline on Cognitive Functioning in Multiple Sclerosis
Mark W. Geisler, PhD;
Martin Sliwinski, PhD;
P. K. Coyle, MD;
David M. Masur, PhD;
Carol Doscher, RN;
Lauren B. Krupp, MD
Arch Neurol. 1996;53(2):185-188.
Abstract
Background
Amantadine hydrochloride and pemoline, both frequently used to treat the fatigue of mutiple sclerosis (MS), may also improve attention and other cognitive functions in MS. To our knowledge, these agents have never been compared in a placebo-controlled trial of patients with MS.
Objective
To evaluate the effects of amantadine and pemoline on cognitive functioning in MS.
Methods
A total of 45 ambulatory patients with MS and severe fatigue were treated for 6 weeks with amantadine, pemoline, or placebo using a parallel group design. They underwent comprehensive neuropsychological testing to determine treatment effects on cognitive functioning. Primary outcome measures were tests of attention (Digit Span, Trail Making Test, and Symbol Digit Modalities Test), verbal memory (Selective Reminding Test), nonverbal memory (Benton Visual Retention Test), and motor speed (Finger Tapping Test).
Results
Fatigue did not significantly correlate with any of the neuropsychological outcome measures at baseline or after treatment. All three treatment groups improved on tests of attention (P<.003), verbal memory (P<.001), and motor speed (P<.002). There were no significant differences between amantadine, pemoline, and placebo.
Conclusions
Cognitive functioning in MS is independent of fatigue. Neither amantadine nor pemoline enhances cognitive performance in MS compared with placebo.
Author Affiliations
From the Departments of Neurology, State University of New York at Stony Brook (Drs Geisler, Coyle, and Krupp and Ms Doscher), and Albert Einstein College of Medicine, Bronx, NY (Drs Sliwinski and Masur).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis
Krupp et al.
Neurology 2011;76:1500-1507.
ABSTRACT
| FULL TEXT
The impact of fatigue on cognitive functioning in patients with multiple sclerosis
Bol et al.
Clin Rehabil 2010;24:854-862.
ABSTRACT
Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial
Lovera et al.
Mult Scler 2010;16:715-723.
ABSTRACT
Donepezil improved memory in multiple sclerosis in a randomized clinical trial
Krupp et al.
Neurology 2004;63:1579-1585.
ABSTRACT
| FULL TEXT
Study and treatment of post Lyme disease (STOP-LD): A randomized double masked clinical trial
Krupp et al.
Neurology 2003;60:1923-1930.
ABSTRACT
| FULL TEXT
Methylphenidate for fatigue in advanced cancer: A prospective open-label pilot study
Sarhill et al.
AM J HOSP PALLIAT CARE 2001;18:187-192.
ABSTRACT
Fatigue and declines in cognitive functioning in multiple sclerosis
Krupp and Elkins
Neurology 2000;55:934-939.
ABSTRACT
| FULL TEXT
Modalities of fatigue in multiple sclerosis: correlation with clinical and biological factors
lriarte et al.
Mult Scler 2000;6:124-130.
ABSTRACT
Fatigue in multiple sclerosis: relationship to depression, disability, and disease pattern
Kroencke et al.
Mult Scler 2000;6:131-136.
ABSTRACT
Recent developments in drug therapy for multiple sclerosis
Smith and Darlington
Mult Scler 1999;5:110-120.
ABSTRACT
|
